Purchase of Measles Rubella (MR) Vaccine Concentrate

The National Institutes of Health (NIH) Islamabad is procuring Measles Rubella (MR) Vaccine Concentrate for the fiscal year 2026-27. This procurement is part of a funded project aimed at enhancing immunization coverage in Pakistan. The procurement is being conducted under the Least Cost Based Selection (LCBS) method in accordance with the Public Procurement Rules, 2004. Items being procured: - Measles Rubella (MR) Vaccine Concentrate The scope of this procurement includes the supply of the vaccine concentrate on F.O.R basis to NIH Islamabad. Bidders must ensure compliance with all technical specifications and quality standards as detailed in the bidding documents available on EPADS v2.0. The procurement process requires submission of sealed bids accompanied by bid security in the form of Pay Order, Call Deposit, or Demand Draft as specified. Eligible bidders must be registered on EPADS v2.0 and comply with all regulatory requirements including FBR registration and relevant experience in vaccine supply. The bidding documents provide detailed terms, conditions, and specifications necessary for participation. The deadline for bid submission is **Wednesday, August 12, 2026 at 11:00 AM**, with bid opening scheduled for the same day at 11:30 AM via EPADS v2.0. Manual bid submissions will not be accepted. Interested vendors who are not yet registered on EPADS v2.0 should complete their registration promptly to avoid disqualification. A practical tip for bidders is to carefully review the bid security requirements and ensure timely submission through the EPADS platform to avoid technical disqualification. Early registration and thorough understanding of the bidding documents will enhance chances of success in this competitive procurement.